Search Result

Results for "

corticotropin releasing factor (CRF)

" in MedChemExpress (MCE) Product Catalog:

標的別:	CRFR (42) Adenylate Cyclase (1) Adrenergic Receptor (1) Bacterial (3) CFTR (7) Drug Derivative (1) Endothelin-Converting Enzyme (ECE) (1) ERK (3) GABA Receptor (1) Isotope-Labeled Compounds (1) NF-κB (3) Parasite (3) Reference Standards (2) Sigma Receptor (1) Vasopressin Receptor (1)
研究分野別:	Cancer (1) Cardiovascular Disease (6) Endocrinology (19) Inflammation/Immunology (4) Metabolic Disease (11) Neurological Disease (32)
クリックケミストリー:	Alkynes (3)

阻害剤およびアゴニスト

ペプチド

組換えタンパク質

同位体標識化合物

クリックケミストリー

Targets Recommended: CRFR GnRH Receptor

製品番号	製品名	Target	研究分野	構造式

HY-106203

Crinecerfont SSR-125543	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P0086

Corticotropin-releasing factor (human) 3 Publications Verification Human CRF; Human corticotropin-releasing factor	CRFR	Neurological Disease
Corticotropin-releasing factor human (Human CRF) stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

HY-P2847

Urocortin II, mouse	CRFR	Metabolic Disease Endocrinology
Urocortin II, mouse is a potent and selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor with K_i** values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca ²⁺/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .

HY-P1752

Urocortin II, human	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human has an effect of promoting satiet and neuroprotective effect. Urocortin II, human also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P0257

Astressin 3 Publications Verification	CRFR	Neurological Disease
Astressin is a potent corticotropin releasing factor (CRF) antagonist.

HY-12127

Pexacerfont BMS-562086	CRFR	Neurological Disease Endocrinology
Pexacerfont is a selective corticotropin-releasing factor (CRF₁) receptor antagonist with IC₅₀ of 6.1±0.6 nM for human CRF₁ receptor.

HY-14875

Verucerfont GSK561679	CRFR	Neurological Disease Endocrinology
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC₅₀s of ~6.1, >1000 and >1000?nM for CRF1, CRF2, and CRF-BP, respectively.

HY-14130

CP 376395	CRFR	Neurological Disease Endocrinology
CP 376395 is a potent, selective, and brain-penetrable **Corticotropin releasing factor 1 (CRF1)** receptor antagonist .

HY-12129

CP 154526 hydrochloride	CFTR	Neurological Disease
CP 154526 hydrochloride is a potent, brain-penetrant and selective **corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i** of 2.7 nM. CP 154526 hydrochloride shows selective for CRF1 over CRF2 (K_i = >10 μM). CP 154526 hydrochloride has anxiolytic activities .

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P2287

Cortagine 3 Publications Verification	CRFR	Neurological Disease
Cortagine is a specific **corticotropin-releasing factor receptor subtype 1 (CRF1) agonist with an EC₅₀** of 2.6 nM for rCRF1. Cortagine is an anxiolytic and antidepressive agent in the mouse model .

HY-P1858A

Urocortin III, mouse TFA	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates *CRF-R2* . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .

HY-113603

Tildacerfont SPR001; LY2371712	CRFR	Metabolic Disease
Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks *CRF1* receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-P1858

Urocortin III, mouse	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates *CRF-R2* . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .

HY-14367

Emicerfont GW876008	CRFR	Neurological Disease Endocrinology
Emicerfont is a corticotropin-releasing factor type 1 (CRF₁) receptor antagonist with an IC₅₀ of 66 nM.

HY-P1298A

Sauvagine TFA	CRFR	Cardiovascular Disease Neurological Disease
Sauvagine TFA is a corticotropin-releasing factor receptor (CRFR) agonist. Sauvagine TFA activates *HM-CRF* receptors to stimulate intracellular cAMP accumulation, activates *PC-CRF* receptors to trigger associated signaling pathways, and stimulates the hypothalamic-pituitary-adrenal axis. Sauvagine TFA can be used for research on central nervous system and blood diseases .

HY-108295

Pivagabine CXB-722	GABA Receptor	Neurological Disease
Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates *CRF-R2* and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

HY-P1752B

Urocortin II, human acetate	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human acetate is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human acetate can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P1533A

CRF, bovine TFA 2 Publications Verification corticotropin releasing factor bovine TFA	CRFR	Inflammation/Immunology Endocrinology
CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [ ¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM .

HY-169914

Igmesine hydrochloride JO 1784 hydrochloride	Sigma Receptor	Neurological Disease
Igmesine hydrochloride (JO 1784) is an orally active σ-receptor ligand capable of blocking the increase in colonic electromechanical activity induced by emotional stress. Igmesine hydrochloride also eliminates the colonic motility stimulation induced by dopamine, as well as the stimulation induced by centrally injected D1 or D2 receptor agonists. Furthermore, Igmesine hydrochloride can block the colonic motility responses induced by corticotropin-releasing factor (CRF) and ES through central cholecystokinin (CCK) release and/or activation of supraspinal CCK pathways .

HY-P1298

Sauvagine	CRFR	Cardiovascular Disease Neurological Disease
Sauvagine is a corticotropin-releasing factor receptor (CRFR) agonist. Sauvagine activates *HM-CRF* receptors to stimulate intracellular cAMP accumulation, activates *PC-CRF* receptors to trigger associated signaling pathways, and stimulates the hypothalamic-pituitary-adrenal axis. Sauvagine can be used for research on central nervous system and blood diseases .

HY-113603S

Tildacerfont-d8 SPR001-d₈; LY2371712-d₈	Isotope-Labeled Compounds CRFR	Cancer
Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks *CRF1* receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-P3019A

Urocortin III (human) TFA	CRFR	Cardiovascular Disease Neurological Disease Metabolic Disease
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates *CRF-R2* and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P3687

[Tyr0] Corticotropin Releasing Factor, ovine	CRFR	Endocrinology
[Tyr0] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor/hormone isolated from ovine. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin .

HY-P3169

a-Helical Corticotropin Releasing Factor (9-41)	CRFR	Inflammation/Immunology
α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor *(CRF)* antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo .

HY-P3683

a-Helical Corticotropin Releasing Factor (12-41)	CRFR	Endocrinology
a-Helical Corticotropin Releasing Factor (12-41) is a 30 amino acids long, α-helical analogue of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH). a-Helical Corticotropin Releasing Factor (12-41) would suppress the stimulatory effect .

HY-12130

CP 154526	CRFR	Neurological Disease
CP 154526 is a potent, brain-penetrant and selective **corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i** of 2.7 nM. CP 154526 shows selective for CRF1 over CRF2 (K_i = >10 μM). CP 154526 has anxiolytic activities .

HY-103378

NBI 35965 methanesulfonate	CRFR	Neurological Disease
NBI 35965 methanesulfonate is a selective, orally active and brain-penetrant **corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i value of 4 nM and a pK_i** value of 8.5. NBI 35965 methanesulfonate does not inhibit CRF2. NBI 35965 methanesulfonate reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC₅₀ values of 7.1 and 6.9, respectively. NBI 35965 methanesulfonate shows anxiolytic effects .

HY-P1533

CRF, bovine corticotropin releasing factor bovine	CRFR	Inflammation/Immunology Endocrinology
CRF, bovine is a potent agonist of CRF receptor, and displaces [ ¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM.

HY-103379

CP 376395 hydrochloride	CRFR	Neurological Disease Endocrinology
CP 376395 hydrochloride is a potent, selective, and brain-penetrable **Corticotropin releasing factor 1 (CRF1)** receptor antagonist .

HY-103376

NBI-27914 hydrochloride	CRFR	Neurological Disease
NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a K_i value of 1.7 nM .

HY-177313

AAG561 NVP-AAG 561	CFTR	Neurological Disease
AAG561 is a **corticotropin-releasing factor receptor 1 (CRF1)** antagonist. AAG561 can be used for the study of the underlying emotion dysregulation of a mental disease or disorder .

HY-12132

DMP 904	CRFR Adenylate Cyclase	Neurological Disease
DMP 904 is a noncompetitive full corticotropin-releasing factor receptor (CRFR) antagonist. DMP 904 can inhibit CRF-stimulated adenylate cyclase activity and ACTH release. DMP 904 exhibits anti-depressant and anti-anxiety activity .

HY-119114

E-2508 free base	CRFR	Neurological Disease
E-2508 free base is an orally active and highly selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist with anxiolytic effects (K_i=11 nM). E-2508 free base blocks CRF-induced cAMP accumulation via CRF1 receptor inhibition. E-2508 free base is promising for research of stress-related psychiatric disorders, such as anxiety and depression .

HY-110310

NGD 98-2 hydrochloride	CRFR	Neurological Disease
NGD 98-2 hydrochloride is an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist

HY-114070

NGD 98-2	CRFR	Neurological Disease
NGD 98-2 is an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist

HY-P3685

[Met(O)21] Corticotropin Releasing Factor, ovine	CRFR	Endocrinology
[Met(O)21] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor isolated from ovine hypothalamic extracts. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH) .

HY-P3684

[DPro5] Corticotropin Releasing Factor, human, rat	CRFR	Endocrinology
[DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-12339

NVS-CRF38	CRFR	Endocrinology
NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility.

HY-123677

E2508	CRFR	Neurological Disease
E2508 is an orally active corticotropin-releasing factor 1 (CRF1) receptor antagonist with a K_i value of 11 nM for hCRF1 .

HY-120148

SM19712 free acid	Endothelin-Converting Enzyme (ECE)	Others
SM19712 (free acid) is an endothelin-converting enzyme-1-related compound that affects corticotropin-releasing factor receptor 1 (CRF1).

HY-12127R

Pexacerfont (Standard) BMS-562086 (Standard)	CRFR Reference Standards	Neurological Disease Endocrinology
Pexacerfont (Standard) is the analytical standard of Pexacerfont. This product is intended for research and analytical applications. Pexacerfont is a selective corticotropin-releasing factor (CRF1) receptor antagonist with IC50 of 6.1±0.6 nM for human CRF1 receptor.

HY-14132

BMS-665053	CRFR	Neurological Disease
BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC₅₀ = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC₅₀ = 4.9 nM) .

HY-162872

NBI-35965	CRFR	Neurological Disease
NBI-35965 is an antagonist of corticotropin-releasing factor receptor 1 (CRF-R1). NBI-35965 can be used in nervous system related research .

HY-P4012

[Asu1,6-Arg8]Vasopressin	Vasopressin Receptor	Endocrinology
[Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture .

HY-P3959

(Tyr0)-Urocortin, rat	CRFR	Endocrinology
(Tyr0)-Urocortin, rat is a high-affinity agonist of corticotropin-releasing factor receptor type 1 (CRF-R1) and type 2 (CRF-R2). (Tyr0)-Urocortin, rat shows inhibitory binding constants (Ki) of 1-2 nM .

HY-110056

NBI 35965 hydrochloride	CRFR	Neurological Disease
NBI 35965 hydrochloride is a selective, orally active and brain-penetrant **corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i value of 4 nM and a pK_i** value of 8.5. NBI 35965 hydrochloride does not inhibit CRF2. NBI 35965 hydrochloride reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC₅₀ values of 7.1 and 6.9, respectively. NBI 35965 hydrochloride shows anxiolytic effects .

HY-103375

SN003	CRFR	Neurological Disease
SN003 is a reversible antagonist of corticotropin releasing factor receptor 1 (CRFR 1) (IC₅₀ = 241 nM) that displays more than 1000-fold selectivity over CRFR 2. SN003 suppresses CRF-induced ACTH release in vitro. SN003 attenuates depressive-like behavior in rat .

HY-118935

NGD9002 free base	Adrenergic Receptor	Inflammation/Immunology
NGD9002 free base is a new generation of selective corticotropin-releasing factor-1 (CRF-1) receptor antagonist with inhibitory activity on CRF-induced colonic function stimulation. NGD9002 free base can reduce CRF-induced fecal output response and show an inhibitory IC50 value of 4.3 mg/kg. NGD9002 free base can effectively block CRF-induced colonic secretory motility stimulation at the highest dose and reduce acute water avoidance-induced defecation. NGD9002 free base can also prevent the occurrence of pain hypersensitivity reactions to repeated colonic distension .

製品番号	製品名	Target	研究分野

HY-P0086

Corticotropin-releasing factor (human) 3 Publications Verification Human CRF; Human corticotropin-releasing factor	CRFR	Neurological Disease
Corticotropin-releasing factor human (Human CRF) stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

HY-P2847

Urocortin II, mouse	CRFR	Metabolic Disease Endocrinology
Urocortin II, mouse is a potent and selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor with K_i** values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca ²⁺/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .

HY-P1752

Urocortin II, human	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human has an effect of promoting satiet and neuroprotective effect. Urocortin II, human also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P0257

Astressin 3 Publications Verification	CRFR	Neurological Disease
Astressin is a potent corticotropin releasing factor (CRF) antagonist.

HY-P2287

Cortagine 3 Publications Verification	CRFR	Neurological Disease
Cortagine is a specific **corticotropin-releasing factor receptor subtype 1 (CRF1) agonist with an EC₅₀** of 2.6 nM for rCRF1. Cortagine is an anxiolytic and antidepressive agent in the mouse model .

HY-P1858A

Urocortin III, mouse TFA	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates *CRF-R2* . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .

HY-P1858

Urocortin III, mouse	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates *CRF-R2* . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .

HY-P1298A

Sauvagine TFA	CRFR	Cardiovascular Disease Neurological Disease
Sauvagine TFA is a corticotropin-releasing factor receptor (CRFR) agonist. Sauvagine TFA activates *HM-CRF* receptors to stimulate intracellular cAMP accumulation, activates *PC-CRF* receptors to trigger associated signaling pathways, and stimulates the hypothalamic-pituitary-adrenal axis. Sauvagine TFA can be used for research on central nervous system and blood diseases .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates *CRF-R2* and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

HY-P1752B

Urocortin II, human acetate	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human acetate is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human acetate can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P1533A

CRF, bovine TFA 2 Publications Verification corticotropin releasing factor bovine TFA	CRFR	Inflammation/Immunology Endocrinology
CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [ ¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM .

HY-P1298

Sauvagine	CRFR	Cardiovascular Disease Neurological Disease
Sauvagine is a corticotropin-releasing factor receptor (CRFR) agonist. Sauvagine activates *HM-CRF* receptors to stimulate intracellular cAMP accumulation, activates *PC-CRF* receptors to trigger associated signaling pathways, and stimulates the hypothalamic-pituitary-adrenal axis. Sauvagine can be used for research on central nervous system and blood diseases .

HY-P3019A

Urocortin III (human) TFA	CRFR	Cardiovascular Disease Neurological Disease Metabolic Disease
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates *CRF-R2* and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P3687

[Tyr0] Corticotropin Releasing Factor, ovine	CRFR	Endocrinology
[Tyr0] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor/hormone isolated from ovine. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin .

HY-P3169

a-Helical Corticotropin Releasing Factor (9-41)	CRFR	Inflammation/Immunology
α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor *(CRF)* antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo .

HY-P3683

a-Helical Corticotropin Releasing Factor (12-41)	CRFR	Endocrinology
a-Helical Corticotropin Releasing Factor (12-41) is a 30 amino acids long, α-helical analogue of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH). a-Helical Corticotropin Releasing Factor (12-41) would suppress the stimulatory effect .

HY-P1533

CRF, bovine corticotropin releasing factor bovine	CRFR	Inflammation/Immunology Endocrinology
CRF, bovine is a potent agonist of CRF receptor, and displaces [ ¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM.

HY-P3685

[Met(O)21] Corticotropin Releasing Factor, ovine	CRFR	Endocrinology
[Met(O)21] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor isolated from ovine hypothalamic extracts. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH) .

HY-P3684

[DPro5] Corticotropin Releasing Factor, human, rat	CRFR	Endocrinology
[DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-P4012

[Asu1,6-Arg8]Vasopressin	Vasopressin Receptor	Endocrinology
[Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture .

HY-P3959

(Tyr0)-Urocortin, rat	CRFR	Endocrinology
(Tyr0)-Urocortin, rat is a high-affinity agonist of corticotropin-releasing factor receptor type 1 (CRF-R1) and type 2 (CRF-R2). (Tyr0)-Urocortin, rat shows inhibitory binding constants (Ki) of 1-2 nM .

HY-P1752A

Urocortin II, human TFA	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human TFA is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human TFA has an effect of promoting satiet and neuroprotective effect. Urocortin II, human TFA also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human TFA can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human TFA can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human TFA can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P11461

Biotin-CRF, human, rat Biotin-corticotropin releasing factor	Drug Derivative	Neurological Disease
Biotin-CRF, human, rat is a biotin-conjugated CRF (human, rat). CRF (human, rat) is a corticotropin-releasing hormone, paraventricular hypothalamic nucleus marker .

製品番号	Compare	製品名	Species	Source	Image

HY-P70013

	CRHBP Protein, Human (HEK293, His) rHucorticotropin-releasing factor-binding protein/CRHBP, His ; corticotropin-releasing factor-Binding Protein; CRF-BP; CRF-Binding Protein; corticotropin-releasing Hormone-Binding Protein; CRH-BP; CRHBP; CRFBP	Human	HEK293
	CRHBP Protein critically regulates by binding to and inactivating corticotropin-releasing factor (CRF), suggesting a role in preventing excessive pituitary-adrenal stimulation, especially during pregnancy. This interaction contributes to balancing neuroendocrine signaling pathways, ensuring appropriate physiological responses and safeguarding against pituitary-adrenal axis overstimulation, particularly in the context of pregnancy. CRHBP Protein, Human (HEK293, His) is the recombinant human-derived CRHBP protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Product


Product	在庫あり - + カートに追加
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 在庫あり - + カートに追加お問い合わせ

製品番号	製品名	構造式

HY-113603S

Tildacerfont-d8

Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

製品番号	製品名		Classification

HY-106203

Crinecerfont SSR-125543		Alkynes
Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride		Alkynes
Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203B

(R)-Crinecerfont (R)-SSR-125543		Alkynes
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: